Background: Responsible use of antimicrobials in equine practice relies on knowledge of common bacterial isolates and their antimicrobial sensitivities.
| INTRODUCTION
Antimicrobial use in veterinary practice has been linked to increased resistance in bacterial infections in both human and veterinary healthcare, 1 and most especially in hospital practice. 2, 3 Clinicians should apply principles of antimicrobial stewardship when considering their choice of antimicrobials, 4 which is not necessarily always the case currently in the United Kingdom (UK). 5 In some other European countries such as Sweden or Denmark, critically important antimicrobials have legally enforced restricted use in veterinary medicine. 6 The British Equine Veterinary Association guidelines for responsible antimicrobial use advise that first-line injectable antimicrobials should be a combination of procaine penicillin with gentamicin sulfate (P-G) in most infectious scenarios encountered in equine practice (www.beva.org.uk/protectme). Among the PO antimicrobials available, a trimethoprim-sulfadiazine (TMPS) combination is recommended for first-line use 7 and is also the only licensed choice in horses in the UK.
Responsible use of antimicrobials is facilitated by in vitro antimicrobial susceptibility testing to inform antimicrobial choice. Breakpoints are determined based on the minimum inhibitory concentration (MIC) of an antimicrobial to separate isolates for which there is a high likelihood of treatment success (sensitive) versus those for which treatment is more likely to be ineffective (intermediate or resistant). 8, 9 International groups including the Clinical and Laboratory Standards Institute (CLSI) and the European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) have published suggested breakpoints for clinical application based on pharmacokinetics and pharmacodynamics to predict clinical efficacy. 10, 11 However, very little specific data are available for horses, requiring some extrapolation from other species. 12 Our aim was to examine the value of in vitro antimicrobial sensitivity testing in antimicrobial selection in both ambulatory and hospital practice. The prevalence of sensitivity to first-line antimicrobials (parenteral P-G and PO TMPS) was determined and subsequently the sensitivity to alternative antimicrobials was examined for the isolates found to be resistant to first-line choices. The hypotheses were that bacteria cultured from a hospital population would have lower prevalence of in vitro sensitivity compared to ambulatory isolates as previously described 9 and that organisms resistant to P-G or TMPS still could be treated successfully with noncritically important antimicrobials such as tetracyclines.
| MATERIALS AND METHODS
In this retrospective analysis, data were collected from all clinical samples submitted to The Liphook Equine Hospital Laboratory for culture and determination of antimicrobial sensitivity between January 2014 and December 2018.
Submitted samples were plated onto Columbia blood agar and
MacConkey's agar, colistin-nalidixic acid agar, or combinations thereof depending on sample type. Subcultures usually were prepared, depending on the purity of primary growth, to obtain pure cultures before suspending individual colonies in saline to a McFarlane standard of 0.5.
The suspension then was processed using a VITEK 2 analyzer (BioMerieux, Basingstoke, Hampshire, UK) for bacterial identification. Isolates were further examined after separating Gram-negative and Grampositive bacteria using a different array of antimicrobials to determine MICs (AST-GN65, AST-GP73, BioMerieux). Antimicrobial susceptibilities were examined across a range of dilutions from 0.5 to 16 μg/mL for gentamicin, 0.06 to 16 μg/mL for benzylpenicillin, 0.1 to 320 μg/mL for trimethoprim-sulfamethoxazole (because sulfadiazine was not available for susceptibility testing on the analyzer used), 0.25 to 16 μg/mL for tetracycline, 0.25 to 8 μg/mL for ceftiofur, and 0.25 to 4 μg/mL for enrofloxacin. Antimicrobial breakpoints were selected from data pro- The population of isolates found to be resistant to P-G was evaluated to determine the prevalence of sensitivity to other antimicrobials that might be selected as a second choice in practice consisting of TMPS, tetracycline, ceftiofur, and enrofloxacin. Not all isolates were tested against every antimicrobial, given that some would not be logical choices based on known pharmacodynamics. For example, gram-negative bacteria were not tested for sensitivity to penicillin. Except for Enterobacter spp, Enterococcus spp was not tested for ceftiofur, and Streptococcus spp was not tested for enrofloxacin and gentamicin. 13, 14 The population of isolates found to be resistant to TMPS was evaluated to determine the prevalence of sensitivity to other antimicrobials that might be selected as a second choice in practice based on known pharmacodynamics comprising tetracycline, ceftiofur, enrofloxacin, or P-G. 
| Statistical analysis

| RESULTS
A total of 6873 isolates were identified and their MICs determined during the study period. Of these, 6354 (92%) came from 345 different ambulatory practices and 519 (8%) came from a single referral hospital population.
| Comparison of ambulatory and referral isolates
Overall 5685 (91%) of the 6354 ambulatory isolates were sensitive to P-G (Table 1) , and 4833 (82%) were sensitive to TMPS ( Table 2) . Of the 519 hospital isolates, 314 (64%) were sensitive to P-G (Table 3) , and 275 (56%) were sensitive to TMPS (Table 4) .
T A B L E 2 Five thousand nine-hundred thirty isolates from 345 ambulatory practices and 489 isolates from a referral hospital tested for Trimethoprim-Sulfamethoxazole (TMPS) sensitivity alongside prevalence of sensitivity (F, female) Prevalence of resistance to P-G was significantly different between ambulatory and referral isolates for all isolates combined (P < .001) as well as for the subcategories of skin/wounds (P < .001), respiratory (P < .001), reproductive female (P < .001), abscesses (P < .001), ocular (P < .001), other (P = .05), and unknown (P < .001).
Prevalence of resistance to TMPS was significantly different between ambulatory and referral isolates for all isolates combined (P < .001), as well as for the subcategories of skin/wounds (P = .003), respiratory (P < .001), reproductive female (P = .01), urinary (P < .001), ocular (P < .001), other (P < .001), and unknown (P < .001).
T A B L E 4 One thousand ninety seven ambulatory isolates found to be resistant to Trimethoprim-sulfamethoxazole (TMPS) and tested for sensitivity to alternative antimicrobials (F, female; P-G, Penicillin-Gentamicin association) 
| Comparison of antimicrobials selected as second choice to resistant isolates
The prevalence of sensitivity to the various second-choice antimicrobials isolates found to be resistant to P-G or TMPS are listed in Tables 3-6 
| DISCUSSION
We found that bacterial isolates collected from ambulatory practice were more likely to be sensitive to P-G and to TMPS than those collected from a referral hospital. We also found that where resistance to first-line antimicrobials was found, no second-choice antimicrobial was consistently predicted to be efficacious, with <68% of the isolates resistant to P-G or TMPS being found to be sensitive to any other antimicrobial.
The finding of higher resistance rates in isolates from a referral hospital compared to those obtained from ambulatory practices (Tables 1-4 ) also has been found in previous studies. 9, 15 This observation probably can be explained because of higher antimicrobial exposure among a hospital bacterial population because resistance genes are put under more environmental pressure as well as other factors such as greater potential for transmission of resistant strains or resistance determinants among hospitalized horses and for stress to precipitate increased shedding of resistant strains. 2 It is especially important to establish MICs for isolates from within a hospital population because of a generally lower likelihood of antimicrobial efficacy. By the same reasoning, it is logical that we found protected antimicrobials such as enrofloxacin and ceftiofur to have a lower prevalence of resistance among isolates because they are used less commonly (Tables 5-8 ). This latter finding might be used incorrectly as justification to employ these antimicrobials more frequently as first-line choices for bacterial infections although the inevitable consequence of such action would be to rapidly increase resistance prevalence to these antimicrobials, leaving little choice thereafter. Enrofloxacin has a relatively limited expected spectrum of activity and is not a reasonable choice for most anerobic or streptococcal infections. 13, 14 In ambulatory cases where MIC data predicted likely failure of P-G treatment, the predicted success of second-choice antimicrobials varied from 35% for tetracyclines to 57% for enrofloxacin, whereas for hospital isolates the equivalent figures were 8% for tetracyclines to 40% for enrofloxacin (Tables 5 and 7 ). In ambulatory cases where MIC data predicted likely failure of TMPS treatment, the predicted success of second choice antimicrobials varied from 37% for tetracycline to 68% for P-G, whereas for hospital isolates the equivalent figures were 23% for tetracyclines to 55% for enrofloxacin ( Tables 6 and 8 ). In ambulatory practice, there may be greater indication for PO antimicrobials for reasons of practicality and therefore preferences for TMPS, doxycycline, or enrofloxacin.
Although enrofloxacin showed lower rates of resistance among the isolates from ambulatory cases compared to the other PO drugs, the rates of resistance nevertheless were high enough to prevent any confidence that enrofloxacin would be efficacious in the absence of determining MIC data. Also, enrofloxacin is not licensed for use in horses, is firmly within the group of critically important antimicrobials, and therefore should be used only with very good evidencebased reasoning. For hospital referral practice, parenteral administration is rarely problematic, meaning that parenteral P-G frequently is used as a first-line choice, and parenteral TMPS or oxytetracycline could be suitable second-choice antimicrobials where resistance is seen to P-G. Although sensitivity rates of P-G-resistant isolates generally were quite poor to TMPS and tetracyclines (11 and 8%, respectively, Table 7 ), these drugs nonetheless should be selected when the MIC is found to be below the clinical breakpoints or when other circumstances exist that might promote efficacy of these drugs (eg, local application). Although where resistance is seen to P-G, TMPS, and oxytetracycline, the further choices of ceftiofur or enrofloxacin might be considered, the sensitivity rates of isolates to these 2 further protected antimicrobials were only 29 and 40%, respectively, reinforcing the fact that they would be poor speculative choices and only should be used based on MIC data.
Strict application of MIC data to predict clinical efficacy or inefficacy sometimes may mislead because the many assumptions underlying the prediction of sensitivity and resistance might not always be correct. The so-called 60-90 rule often is quoted as a guide, which states that bacterial infections with in vitro prediction of efficacy to a particular antimicrobial will resolve in 90% of patients treated with that antimicrobial, whereas 60% of bacterial isolates with predicted resistance still might respond well. 16 There are many instances and reasons why bacteria with apparent in vitro resistance to an antimicrobial actually might respond well clinically to that antimicrobial. These factors include the host's own immunity, which contributes to bacterial clearance, but also pharmacokinetic properties that might favor antimicrobial accumulation at a particular site of infection. For example, urinary excretion of TMPS and P-G will lead to especially high urinary concentrations and clinical efficacy against urinary tract isolates even when in vitro testing might suggest resistance. 17, 18 This divergence between in vitro test results and clinical efficacy is likely to be even more pronounced for infections that are amenable to topical or local treatments (eg, intra-ocular, intra-uterine, dermal, IV regional perfusion) because local concentrations will be many times higher than could be achieved by systemic administration. For example, an isolate with an MIC for gentamicin of 16 μg/mL would be predicted to be highly resistant based on efficacy requiring attainment of 128 to 160 μg/mL gentamicin (8-10 times the MIC) in the locality of the infection, which is unachievable with systemic administration. 9 However, such local concentrations are relatively easily achievable by topical treatment. 19 Local treatments also will decrease the incidence of adverse effects on the fecal microbiota and the development of antimicrobial-associated diarrhea. 20 Another important consideration is the synergistic action of some antimicrobial combinations leading to better clinical efficacy than would be expected based on the spectrum of each antimicrobial taken separately. 21 For example, trimethoprim and penicillin demonstrate synergism when given along with aminoglycosides. 22 Conversely, there are instances and reasons why bacteria with apparent in vitro sensitivity to an antimicrobial may not respond well clinically to that antimicrobial. Infections may occur at sites poorly accessible to the chosen antimicrobial or potentially antagonistic factors may impair the pharmacodynamic properties of the antimicrobial in question. [23] [24] [25] Additionally, suppressive or antagonistic drug interactions can occur when poorly selected polypharmacy is employed. 26 A further intriguing strategy for improving antimicrobial sensitivity involves the concept of collateral drug sensitivity where a bacterial strain that has acquired resistance to 1 class of antimicrobials (especially aminoglycosides) may sometimes simultaneously become more sensitive to other antimicrobials. [27] [28] [29] Prudent use of antimicrobials hopefully will promote good efficacy in clearing bacterial infections while limiting the increase in bacterial resistance. 30 Our study reconfirmed previous evidence of higher rates of antimicrobial resistance in isolates from an equine hospital compared to ambulatory practices. Additionally, we found that when resistance was found to first-line antimicrobial choices, the choice of subsequent antimicrobials could not be predicted with confidence and always should be based on MIC data rather than speculation.
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